Gregory J. Divis, President and Chief Executive Officer of InMed Pharmaceuticals Inc. (now Mentari Therapeutics, Inc.), filed an initial statement of beneficial ownership on November 12, 2026, reporting a stock option position received in connection with a corporate merger effective November 6, 2026.

Key Highlights

  • Reporting person: Gregory J. Divis, serving as President and Chief Executive Officer, and also listed as a Director of the issuer.
  • Triggering event date: November 6, 2026, the effective date of the merger described in the filing.
  • Derivative security disclosed: A stock option (right to buy) covering 1,454,398 shares of common stock, held directly.
  • Exercise price: $10.37 per share, with an expiration date of September 24, 2036.
  • Option origin: The options were received in the merger in exchange for options of Pre-Merger Mentari held by Divis prior to the merger, according to the filing.
  • Vesting schedule: 25% vests on July 20, 2027, with the remainder vesting in equal monthly installments through July 20, 2030, subject to continued service.
  • No non-derivative securities: Table I of the filing lists no directly or indirectly held non-derivative securities.

Divis Discloses Merger-Issued Options in Initial Ownership Filing

According to the filing, the issuer is InMed Pharmaceuticals Inc., trading on NASDAQ:MTRI, which the filing identifies as "formerly known as InMed Pharmaceuticals Inc." and now operating under the name Mentari Therapeutics, Inc. The filing explains that effective November 6, 2026, Indigo Merger Sub Corp., a wholly owned subsidiary of the issuer, merged with and into Mentari Therapeutics, Inc., a Delaware corporation referred to as "Pre-Merger Mentari," with Pre-Merger Mentari continuing as a wholly owned subsidiary of the issuer and the surviving corporation of the first merger.

The filing further states that immediately after the first merger, Pre-Merger Mentari merged with and into Indigo Merger Sub II, LLC, a second wholly owned subsidiary of the issuer, with that entity surviving as Mentari Therapeutics Operating Company LLC. The filing refers to both steps collectively as "the Merger." As a result of this transaction, Divis received stock options to purchase 1,454,398 shares of the issuer's common stock at an exercise price of $10.37, in exchange for options previously held in Pre-Merger Mentari. The option is held directly and expires September 24, 2036.

The vesting terms disclosed in the filing require 25% of the option to vest on July 20, 2027, with the remaining shares vesting in equal monthly installments through July 20, 2030, contingent on Divis's continued service to the issuer on each vesting date. The form was signed on November 12, 2026, by Jerad G. Seurer as attorney-in-fact for Gregory Divis.

What Was Disclosed

This Form 3 filing discloses Gregory J. Divis's initial beneficial ownership of a stock option covering 1,454,398 shares at $10.37 per share, received through a merger effective November 6, 2026, with no non-derivative securities reported.